Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL
Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL
Active, not recruiting · NCT07393204 · Registry updated 2026-02-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Not stated | 2026-02-06 | NCT07393204 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Andrés José Maria Ferreri | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| IRCCS Ospedale San Raffaele | Milan | Italy | 47 |